The development of the domestic innovative drug industry is accelerating, and the pharmaceutical machine industry is ushering in abundant development opportunities

[Pharmaceutical Network Market Analysis] In recent years, with the support of national policies and the booming biopharmaceutical market, the domestic innovative drug industry has begun to enter a period of accelerated grow.
At present, regardless of multinational pharmaceutical giants, domestic pharmaceutical companies, or small and medium-sized innovative R&D companies, they are constantly increasing their layout in China's innovative drug mark.
According to incomplete statistics, there were more than 300 investment and financing events in the first half of the ye.
Among them, there were 161 financing events in the field of innovative drugs, 34 financing events focused on cell therapy, and 14 financing events with an amount of more than 100 million yu.
In addition, there were 26 financing events in gene therapy, of which 10 financing events exceeded 100 million yu.

At present, as a large number of pharmaceutical companies continue to strengthen R&D investment and steadily promote clinical research on innovative drugs, more and more innovative drug projects are beginning to usher in resul.
For example, on July 18, Renfu Pharmaceutical issued an announcement saying that its application for the clinical trial of its class 1 new drug RFUS-144 injection was approved by the Food and Drug Administration for the treatment of prurit.
It is understood that RFUS-144 injection is clinically intended for the treatment of pain and pruritus, and is a selective opioid receptor agoni.
On July 13, Zai Lab announced that the CDE has accepted the marketing application of efgartigimod for the treatment of generalized myasthenia gravis (M.
This is the first FcRn inhibitor approved by the FDA in the world, and the first approved therapy specifically for the treatment of systemic MG through endogenous reduction of pathogenic antibodi.
In addition, since the beginning of this year, Hengrui Medicine has also obtained clinical approvals for 25 new drugs, including pyrotinib maleate tablets, adebelimumab injection, HRS-1167 tablets, and irinotecan hydrochloride liposome injecti.
43 acceptance numbers are involv.
The industry believes that with the support of policies and the continuous entry of pharmaceutical companies, China's pharmaceutical industry may enter a stage of accelerating innovation and development, and at the same time, the demand for pharmaceutical R&D and production will also continue to increa.
In this case, China's pharmaceutical equipment industry is also expected to usher in huge opportuniti.
In fact, many pharmaceutical equipment companies have already begun to focus on innovative drugs and have begun to develop high-end equipment and biomedical equipme.
For example, at the end of last year, Canaan Technology stated on the investor interaction platform that the company's current business segment includes innovative pharmaceutical water equipment for biological preparations and pharmaceutical liquid dispensing system engineering business; in the future, the company will rely on pharmaceutical water equipment and pharmaceutical liquid dispensing system busine.
Extend the industrial chain to the front-end and back-end equipment of biological dru.
Since 2021, Tofflon has also accelerated the integration of packing, filtration and other links in the production of biological drugs (such as Suzhou Haiwei, Qianchun Biology, e.

In February 2022, the company disclosed the fixed increase plan, and plans to raise 2 billion yuan to invest in the "Biopharmaceutical Equipment Industry Trial Production Center" and "Jiangsu Biomedical Equipment Industrialization Bas.
It is worth mentioning that in terms of research and development, Tofflon will increase a number of research and development projects in 2021, and the research and development expenses will reach 285 million yuan, a year-on-year increase of 82
Chutian Technology is a domestic pharmaceutical equipment manufactur.
At present, it has a rich product line covering eight major product modules such as bioengineering and sterile preparations and dozens of product typ.
However, it still said that in 2022, the company will increase its efforts to maintain the domestic advantages of aseptic packaging and post-test packaging products; focus on the development of biomedical equipment, especially biopharmaceutical front-end bioreactors and their disposable technology (SUT) products, Consumables, packaging materials, auxiliary materials; establish an innovative drug equipment development team to develop intelligent new produc.
In addition, Xinma Drying has taken "industry technological innovation" as the core in recent yea.
Through the continuous introduction and training of talents, it has done a good job in teaching and mentoring, vigorously cultivated new technical personnel, and boldly appointed young technical backbon.
A technical team with the old and the new, the talents coming out in large numbers, and the practice and innovati.
It is reported that with a professional technical team, the company has strong technical strength and can design, manufacture and install complete sets of engineering equipment according to customer nee.
Among them, protein peptide spray dryers, closed-circuit centrifugal spray dryers, vibrating fluidized bed dryers, pulse vacuum dryers, boiling dryers and other products have been well received in the industry for their technology and performan.
In general, innovation is the basis for enterprises to obtain competitiveness and economic benefits, and to survive and devel.
In the context of increasingly fierce competition in the pharmaceutical market, more new opportunities in the field of equipment will be brought, and in order to seize these opportunities, companies need to rely on innovation to continuously improve their technical streng.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.